Accure Therapeutics strengthens its scientific advisory board with top-class experts
Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of five world-class neurology experts to its scientific advisory board.
They will help boost innovation and advocate for Accure Therapeutics, as the company drives the advancement of its clinical trials and the development of new treatments.
The appointees are: Stephen L. Hauser, director of the Weil Institute for Neuroscience at UCSF (University of California, San Francisco); Larry Steinman, former chair of the immunology program at Stanford University and member of the National Academy of Sciences and National Academy of Medicine; Amit Bar-Or, director of the Center for Neuroinflammation and Neurotherapeutics, Perelman School of Medicine at the University of Pennsylvania; José Obeso, director of CINAC Neuroscience Center in Madrid; and Lawrence Hirsch, chief of the division of epilepsy and EEG at Yale University School of Medicine and co-director at Yale Comprehensive Epilepsy Centre.
“We are proud and delighted with the appointment of our expert scientific advisory board members; each of whom is a highly experienced pioneer within his field of expertise. Their exceptional skills, talent and experience will help us to steer and refine the direction of our development. Their combined connections in academia and industry will help us establish instrumental partnerships,” said Pablo Villoslada, CSO of Accure Therapeutics.
According to Prof. Stephen L. Hauser: “The Accure team is fantastic, and the company is well-positioned to become a leader in CNS therapeutics. Disorders of the brain represent the next great area for growth in biotechnology. As scientific advisors, we will collectively address the largely unmet needs for disease modifying therapies and help position Accure for success in developing innovative drugs against serious brain disorders that affect more than one billion people worldwide.”
Accure Therapeutics, a European company with an international mindset, already has in its portfolio three new chemical entities, potential disease-modifying drug candidates because they address key dysregulations in CNS biology, with the potential to accommodate more. It is one of the few EU companies that operate in an agnostic fashion on initial science to deliver new disease modifying drugs in CNS. The latest scientific advisory board appointments will strengthen the company’s vision and future plans.
» For further information: Accure Therapeutics website [+]